Everolimus in patients with metastatic renal cell carcinoma previously treated with bevacizumab: a prospective multicenter study CRAD001LRU02T⃰

Everolimus is an orally administered inhibitor of the mammalian target of rapamycin (mTOR) recommended for patients with metastatic renal cell carcinoma (mRCC) who progressed on previous vascular endothelial growth factor (VEGF) receptor-tyrosine kinase inhibitor therapy. Efficacy of everolimus in patients who progressed on anti-VEGF monoclonal antibody bevacizumab is unknown. We did a multicenter prospective trial of everolimus in patients with mRCC whose disease had progressed on bevacizumab ± interferon alpha (IFN). Patients with clear-cell mRCC which had progressed on bevacizumab ± IFN received everolimus 10 mg once daily. The primary end point was the proportion of patients remaining progression-free for 56 days, and a two-stage Simon design was used, with 80 % power and an alpha risk of 5 %. This study is registered with ClinicalTrials.gov, number NCT02056587. From December 2011 to October 2013, a total of 37 patients (28 M, 9 F) were enrolled. Median age was 60.5 years (range 41-66), 11 % had Eastern Cooperative Oncology Group Performance Status (ECOG PS) > 2, and Memorial Sloan-Kettering Cancer Center (MSKCC) favorable/intermediate risk was 38/62 %. Five (14 %) patients had a confirmed partial response and 26 (70 %) patients had a stable disease. Median progression-free survival was 11.5 months (95 % CI, 8.8–14.2). Median overall survival was not reached. No grade 3 or 4 treatment-related toxicities were observed. The most common grade 2 adverse events were fatigue (19 %) and pneumonitis (8 %). Everolimus demonstrated a favorable toxicity profile and promising anti-tumor activity as a second-line therapy in metastatic renal cell carcinoma (RCC) patients previously treated with bevacizumab ± IFN.

1. Motzer R.J., Hutson T.E., Tomczak P. et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115–24.

2. Sternberg C.N., Davis I.D., Mardiak J. et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010;28(6):1061–8.

3. Rini B.I., Halabi S., Rosenberg J.E. et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol2010;28(13):2137–43.

4. Escudier B., Pluzanska A., Koralewski P. et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007;370(9605):2103–11.

5. Motzer R.J., Escudier B., OudardS. etal. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372(9637):449–56.

6. Goss P.E., Strasser-Weippl K., Lee-Bychkovsky B.L. et al. Challenges to effective cancer control in China, India, and Russia. Lancet Oncol 2014;15:489–538.

7. Tsimafeyeu I., Wynn N., Gordiyev M., Khasanova A. FGFR2 expression and mutation are rare in papillary renal cell carcinoma [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10;Washington, DC. Philadelphia (PA): AACR; Cancer Res2013;73(8 Suppl): Abstract nr 4069. doi:10.1158/1538-7445.AM2013-4069.

8. Tsimafeyeu I., Zart J.S., Chung B. Cytoreductive radiofrequency ablation in patients with metastatic renal cell carcinoma (RCC) with small primary tumours treated with sunitinib or interferon-α. BJU International 2013;112 (1):32–8.

9. Escudier B., Eisen T., Porta C. et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012;23(suppl 7): vii65–vii71.

10. Rini B.I., Escudier B., Tomczak P. et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 2011;378(9807):1931–9.

11. Motzer R.J., Escudier B., Tomczak P. et al. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol 2013;14:552–62.

12. Thiery-Vuillemin A., Theodore C., Jacobasch L. et al. Efficacy and safety of sequential use of everolimus (EVE) in patients (pts) with metastatic renal cell carcinoma (mRCC) previously treated with bevacizumab (BEV) with or without interferon (INF)therapy: overall survival (OS) result from the European AVATOR retrospective study. J Clin Oncol 2013;31 (suppl; abstr e15607).

13. Signorovitch J.E., Vogelzang N.J., Pal S.K. et al. Comparative effectiveness of second-line targeted therapies for metastatic renal cell carcinoma: synthesis of findings from two multi-practice chart reviews in the United States. Curr Med Res Opin2014;27:1–11.

14. Iacovelli R., Santoni M., Verzoni E. et al. Everolimus and temsirolimus are not the same second-line in metastatic renal cell carcinoma. A systematic review and metaanalysis of literature data. Clin Genitourin Cancer2014 Aug 2; pii: S1558- 7673(14)00153-0. doi:10.1016/j.clgc.2014.07.006.

15. 15. Motzer R.J., Barrios C.H., Kim T.M. et al. Record-3: phase II randomized trial comparing sequential first-line everolimus (EVE) and second-line sunitinib (SUN) versus first-line SUN and second-line EVE in patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol2013;31 (suppl; abstr 4504).

16. Calvo E., Escudier B., Motzer R.J. etal. Everolimus in metastatic renal cell carcinoma: subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study. Eur J Cancer 2012;48(3):333–9.

17. Motzer R.J., Escudier B., Oudard S. et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis ofprognostic factors. Cancer 2010;116(18):4256–65.

18. vious vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study. Eur J Cancer 2012;48(3):333–9.

19. Motzer R. J., Escudier B., Oudard S. et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis ofprognostic factors. Cancer 2010;116(18):4256–65.